Research institution
University Health Network, Toronto Clinical Trials
Studies where University Health Network, Toronto is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 257Patient Engagement, Patient Activation
At-home Breast Oncology Care Delivered With E-health Solutions
The COVID-19 pandemic has significantly impacted healthcare service delivery, highlighting the need for high quality virtual patient care.
- Conditions
- Patient Engagement, Patient Activation, Patient Reported Outcome Measures
- Trial name
- ABODE (NCT05989477)
- Testing
- At-home Breast Oncology care Delivered with E-health solutions - ABODE
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- University Health Network, Toronto
Breast Cancer
Sentinel lympH Node Biopsy With Indocyanine Green in Breast Cancer After NEoadjuvant Chemotherapy (SHINE)
This is a prospective, open-label, within-patient clinical trial to determine the accuracy of Indocyanine green (ICG) guided sentinel lymph node biopsy (SLNB) compared to the standard dual-tracer SLNB in breast cancer patients…
- Trial name
- SHINE (NCT06085274)
- Testing
- ICG guided sentinel lymph node biopsy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Triple-Negative Breast Cancer (TNBC)
Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC
This study is a phase I/II open-label randomized clinical trial to examine whether administration of isunakinra (EBI-005), a modified recombinant IL1 receptor antagonist, can sensitize human TNBC to the PD1…
- Trial name
- NCT07698106
- Testing
- Group 1-Isunakinra
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University Health Network, Toronto
T2D
Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes
The study aims to determine the acute efficacy and safety of three sequential doses of acetazolamide (62.5 mg, 125 mg, 250 mg) each for 2 weeks in 20 patients with T2D receiving background SGLT2i therapy.
- Trial name
- DIPPER Pilot (NCT07902726)
- Testing
- Acetazolamide 62.5 mg, Acetazolamide 125 mg, Acetazolamide 250 mg
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Spinal Cord Injuries (SCI)
Functional Electrical Stimulation Plus High Intensity Interval Training at Home
People living with SCI may experience loss of sensation, movement and regular body function. One way to address these impairments is activity-based therapy (ABT), which includes movement-based activities that promote the…
- Trial name
- NCT07773974
- Testing
- FES+HIIT@Home
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- University Health Network, Toronto
Hepatocellular Carcinoma (HCC)
Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma
This study evaluates whether Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) improves overall survival compared with best supportive care (BSC).
- Trial name
- PULSAR-HCC (NCT07895732)
- Testing
- Best Supportive Care (BSC), Personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR)
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University Health Network, Toronto
Glottic Carcinoma
Volumetric Adaptive SBRT Versus Conventional Accelerated Radiation Therapy for Early-Stage Glottic Cancer
This non-inferiority trial will compare conventional long-course accelerated fractionation radiation therapy (AF-RT) with volumetric adaptive stereotactic body radiation therapy (SBRT) in patients with early-stage (cT1-2N0M0)…
- Trial name
- VOICE (NCT07895745)
- Testing
- Long course accelerated fractionation radiation therapy, Adaptive stereotactic body radiation therapy
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- University Health Network, Toronto
Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication
Platform of Randomized Adaptive Clinical Trials in Critical Illness
PRACTICAL is a randomized multifactorial adaptive platform trial for acute hypoxemic respiratory failure (AHRF). This platform trial will evaluate novel interventions for patients with AHRF across a range of severity states…
- Conditions
- Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
- Trial name
- PRACTICAL (NCT05440851)
- Testing
- Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL)
- Where
- 103 sites in United States, Australia and 8 more
- Volunteers
- 6,250 people
- Sponsor
- University Health Network, Toronto
Autoimmune Hepatitis
Belimumab in Autoimmune Hepatitis
Background: Autoimmune hepatitis (AIH) is a rare chronic and lifelong liver disease. Untreated, disease progresses to end-stage cirrhosis and the focus of therapy is with immunosuppression.
- Trial name
- BELief (NCT06381453)
- Testing
- Belimumab Auto-Injector [Benlysta]
- Where
- 6 sites in Canada
- Volunteers
- 48 people
- Sponsor
- University Health Network, Toronto
Extubation
EXtubation Related Complications - the EXTUBE Study (EXTUBE)
EXTUBE is an international, multicentre, prospective cohort study evaluating the incidence, risk factors, and outcomes of extubation-related complications and describing clinical practices related to extubation after general…
- Trial name
- EXTUBE (NCT06442930)
- Where
- 35 sites in United States, Australia and 7 more
- Volunteers
- 3,000 people
- Sponsor
- University Health Network, Toronto
Completed, with results posted
All –Kidney Transplant Recipients, Post-transplant Diabetes Mellitus
Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients
This study will be a randomized, double-blind, placebo-controlled clinical trial comparing the SGLT2 inhibitor dapagliflozin to placebo in 52 kidney transplant recipients (KTR) with or without pre-existing type 2 diabetes (T2D)…
- Conditions
- Kidney Transplant Recipients, Post-transplant Diabetes Mellitus, Type 2 Diabetes
- Trial name
- INFINITI2019 (NCT04965935)
- Testing
- Dapagliflozin 10 MG Oral Tablet
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- University Health Network, Toronto
Lungcancer
A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
MEK162 has shown significant inhibition of tumor growth as a single agent in NSCLC xenograft models in mice and human cancer cells in vitro, which have KRAS and/or other mutations.
- Trial name
- MEK162 (NCT02185690)
- Testing
- Binimetinib, Pemetrexed, Carboplatin
- Where
- 4 sites in Canada
- Volunteers
- 13 people
- Sponsor
- University Health Network, Toronto
Type 2 Diabetes Mellitus, Heart Failure
ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure
This study aims to elucidate the mechanisms whereby the SGLT2i "ertugliflozin" modifies cardiorenal interactions that regulate fluid volume and neurohormonal activation in patients with type 2 diabetes and heart failure (T2D-HF).
- Trial name
- ERADICATE-HF (NCT03416270)
- Testing
- Ertugliflozin
- Where
- 3 sites in Canada, Netherlands
- Volunteers
- 34 people
- Sponsor
- University Health Network, Toronto
Obstructive Sleep Apnea
Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications
Sugammadex or neostigmine are given at the end of the surgery to reverse neuro muscular blocking drugs (NMBD). This study will evaluate whether reversal of NMBD with sugammadex is associated with faster recovery than neostigmine…
- Trial name
- Sugammadex (NCT03679611)
- Testing
- Sugammadex Sodium, Neostigmine
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto
Osteoporosis, HIV
Bone Health in Aging HIV Infected Women
Design: Open-label randomised multicenter international strategic trial of older women on combination antiretroviral therapy (cART) containing tenofovir-emtricitabine (TDF/FTC) with HIV RNA suppression for > 6 months to : 1.
- Conditions
- Osteoporosis, HIV, Menopause
- Trial name
- BEING (NCT02815566)
- Testing
- tenofovir-alafenamide-emtricitabine, tenofovir-emtricitabine
- Where
- 7 sites in Canada, Italy
- Volunteers
- 34 people
- Sponsor
- University Health Network, Toronto